Abstract

Stroke is one of the most common causes of disability and lack of independence in activities of daily living in adults.One of the most important factors predisposing to stroke, besides hypertension and atrial fibrillation, is carotid atherosclerosis. Rupture of unstable plaque with formation of a platelet plug is the cause of about 20-25% of ischemic strokes. Osteoprotegerin (OPG) is an important regulator of bone remodeling under physiological and disease conditions, as well as the regulator of osteoclast differentiation. Elevated plasma OPG level is associated with increased risk of ischemic stroke and heart diseases, including atrial fibrillation, and is observed in patients with symptomatic carotid artery stenosis and atherosclerotic vulnerable plaques. Furthermore, the occurrence of certain genotypes of OPG is 10 times more common in people with unstable atherosclerotic plaque, making them an independent risk predictor of plaque instability. This article summarizes the current state of knowledge on the potential role of OPG as a biomarker and prognostic indicator of stroke.

References

• 1. Baud’huin M., Duplomb L., Teletchea S., Lamoureux F., Ruiz-VelascoC., Maillasson M., Redini F., Heymann M.F., Heymann D.: Osteoprotegerin:multiple partners for multiple functions. Cytokine GrowthFactor Rev., 2013; 24: 401-409
  Google Scholar
• 2. Ben-Tal Cohen E., Hohensinner P.J., Kaun C., Maurer G., Huber K.,Wojta J.: Statins decrease TNF-α-induced osteoprotegerin productionby endothelial cells and smooth muscle cells in vitro. Biochem.Pharmacol., 2007; 73: 77-83
  Google Scholar
• 3. Bennett B.J., Scatena M., Kirk E.A., Rattazzi M., Varon R.M., AverillM., Schwartz S.M., Giachelli C.M., Rosenfeld M.E.: Osteoprotegerininactivation accelerates advanced atherosclerotic lesion progressionand calcification in older ApoE-/- mice. Arterioscler. Thromb. Vasc.Biol., 2006; 26: 2117-2124
  Google Scholar
• 4. Biscetti F., Straface G., Giovannini S., Santoliquido A., Angelini F.,Santoro L., Porreca C.F., Pecorini G., Ghirlanda G., Flex A.: Associationbetween TNFRSF11B gene polymorphisms and history of ischemicstroke in Italian diabetic patients. Hum. Genet., 2013; 132: 49-55
  Google Scholar
• 5. Bogucki M., Gierczyński J., Gryglewicz J., Karczewicz E., ZalewskaH.: Udary mózgu – konsekwencje społeczne i ekonomiczne. WydawnictwoUczelni Łazarskiego, Warszawa 2013
  Google Scholar
• 6. Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., BlahaM.J., Dai S., Ford E.S., Fox C.S., Franco S., Fullerton H.J., Gillespie C.,Hailpern S.M., Heit J.A., Howard V.J. i wsp.: Heart disease and strokestatistics – 2014 update: a report from the American Heart Association.Circulation, 2014; 129: e28-e292
  Google Scholar
• 7. Goldstein L.B., Bushnell C.D., Adams R.J., Appel L.J., Braun L.T.,Chaturvedi S., Creager M.A., Culebras A., Eckel R.H., Hart R.G.,Hinchey J.A., Howard V.J., Jauch E.C., Levine S.R., Meschia J.F. i wsp.:Guidelines for the primary prevention of stroke: a guideline forhealthcare professionals from the American Heart Association/American Stroke Asociation. Stroke, 2011; 42: 517-584
  Google Scholar
• 8. Golledge J., McCann M., Mangan S., Lam A., Karan M.: Osteoprotegerinand osteopontin are expressed at high concentrations withinsymptomatic carotid atherosclerosis. Stroke, 2004; 35: 1636-1641
  Google Scholar
• 9. Guldiken B., Guldiken S., Turgut B., Turgut N., Demir M., Celik Y.,Arikan E., Tugrul A.: Serum osteoprotegerin levels in patients withacute atherothrombotic stroke and lacunar infarct. Thromb. Res.,2007; 120: 511-516
  Google Scholar
• 10. Halliday A., Harrison M., Hayter E., Kong X., Mansfield A., MarroJ., Pan H., Peto R., Potter J., Rahimi K., Rau A., Robertson S., StreiflerJ., Thomas D.; Asymptomatic Carotid Surgery Trial (ACST) CollaborativeGroup: 10-year stroke prevention after successful carotidendarterectomy for asymptomatic stenosis (ACST-1): a multicentrerandomised trial. Lancet, 2010; 376: 1074-1084
  Google Scholar
• 11. Holecki M., Zahorska-Markiewicz B., Janowska J., Mizia-Stec K.,Żak-Gołąb A., Olszanecka-Glinianowicz M., Wojaczyńska-Stanek K.,Nieszporek T., Więcek A.: Osteoprotegerin – does it play a protectiverole in the pathogenesis of bone loss in obese perimenopausalwomen? Endokrynol. Pol., 2007; 58: 7-10
  Google Scholar
• 12. Jensen J.K., Ueland T., Atar D., Gullestad L., Mickley H., Aukrust P.,Januzzi J.L.: Osteoprotegerin concentrations and prognosis in acuteischaemic stroke. J. Intern. Med., 2010; 267: 410-417
  Google Scholar
• 13. Jiang J.Q., Lin S., Xu P.C., Zheng Z.F., Jia J.Y.: Serum osteoprotegerinmeasurement for early diagnosis of chronic kidney diseasemineraland bone disorder. Nephrology, 2011; 16: 588-594
  Google Scholar
• 14. Kadoglou N.P., Gerasimidis T., Golemati S., Kapelouzou A., KarayannacosP.E., Liapis C.D.: The relationship between serum levelsof vascular calcification inhibitors and carotid plaque vulnerability.J. Vasc. Surg., 2008; 47: 55-62
  Google Scholar
• 15. Kazama J.J., Shigematsu T., Yano K., Tsuda E., Miura M., IwasakiY., Kawaguchi Y., Gejyo F., Kurokawa K., Fukagawa M.: Increasedcirculating levels of osteoclastogenesis inhibitory factor (osteoprotegerin)in patients with chronic renal failure. Am. J. Kidney Dis.,2002; 39: 525-532
  Google Scholar
• 16. Kiechl S., Schett G., Wenning G., Redlich K., Oberhollenzer M.,Mayr A., Santer P., Smolen J., Poewe W., Willeit J.: Osteoprotegerinis a risk factor for progressive atherosclerosis and cardiovasculardisease. Circulation, 2004; 109: 2175-2180
  Google Scholar
• 17. Kim J., Song T.J., Yang S.H., Lee O.H., Nam H.S., Kim Y.D., KimE.H., Lee H.S., Nam C.M., Heo J.H.: Plasma osteoprotegerin levelsincrease with the severity of cerebral artery atherosclerosis. Clin.Biochem., 2013; 46: 1036-1040
  Google Scholar
• 18. Mesquita M., Demulder A., Damry N., Mélot C., WittersheimE., Willems D., Dratwa M., Bergmann P.: Plasma osteoprotegerin isan independent risk factor for mortality and an early biomarkerof coronary vascular calcification in chronic kidney disease. Clin.Chem. Lab. Med., 2009; 47: 339-346
  Google Scholar
• 19. Mogelvang R., Haahr-Pedersen S., Bjerre M., Frystyk J., IversenA., Galatius S., Flyvbjerg A., Jensen J.S.: Osteoprotegerin improvesrisk detection by traditional cardiovascular risk factors and hsCRP.Heart, 2013; 99: 106-110
  Google Scholar
• 20. Musialek P., Tracz W., Tekieli L., Pieniazek P., Kablak-ZiembickaA., Przewlocki T., Stepien E., Kapusta P., Motyl R., Stepniewski J., UndasA., Podolec P.: Multimarker approach in discriminating patientswith symptomatic and asymptomatic atherosclerotic carotid arterystenosis. J. Clin. Neurol., 2013; 9: 165-175
  Google Scholar
• 21. Noheria A., Mosley T.H.Jr., Kullo I.J.: Association of serum osteoprotegerinwith left ventricular mass in African-American adultswith hypertension. Am. J. Hypertens., 2010; 23: 767-774
  Google Scholar
• 22. Nybo M., Johnsen S.P., Dethlefsen C., Overvad K., TjønnelandA., Jørgensen J.O., Rasmussen L.M.: Lack of observed associationbetween high plasma osteoprotegerin concentrations and ischemic stroke risk in a healthy population. Clin. Chem., 2008; 54: 1969-1974
  Google Scholar
• 23. Oh E.S., Rhee E.J., Oh K.W., Lee W.Y., Baek K.H., Yoon K.H., KangM.I., Yun E.J., Park C.Y., Choi M.G., Yoo H.J., Park S.W.: Circulatingosteoprotegerin levels are associated with age, waist-to-hip ratio,serum total cholesterol, and low-density lipoprotein cholesterol levelsin healthy Korean women. Metabolism, 2005; 54: 49-54
  Google Scholar
• 24. Omland T., Drazner M.H., Ueland T., Abedin M., Murphy S.A.,Aukrust P., de Lemos J.A.: Plasma osteoprotegerin levels in the generalpopulation: relation to indices of left ventricular structure andfunction. Hypertension, 2007; 49: 1392-1398
  Google Scholar
• 25. Sacco R.L., Kasner S.E., Broderick J.P., Caplan L.R., Connors J.J.,Culebras A., Elkind M.S., George M.G., Hamdan A.D., Higashida R.T.,Hoh B.L., Janis L.S., Kase C.S., Kleindorfer D.O., Lee J.M. i wsp.: Anupdated definition of stroke for the 21st century: a statement forhealthcare professionals from the American Heart Association/American Stroke Association. Stroke, 2013; 44: 2064-2089
  Google Scholar
• 26. Schnabel R.B., Larson M.G., Yamamoto J.F., Kathiresan S., Rong J.,Levy D., Keaney J.F. Jr., Wang T.J., Vasan R.S., Benjamin E.J.: Relationof multiple inflammatory biomarkers to incident atrial fibrillation.Am. J. Cardiol., 2009; 104: 92-96
  Google Scholar
• 27. Seremak-Mrozikiewicz A., Tatuśko J., Drews K., Barlik M., KrajewskiP., Spaczyński M., Mrozikiewicz P.M.: Polymorphism of osteoprotegeringene and osteoporosis in postmenopausal women. Ginekol.Pol., 2009; 80: 354-360
  Google Scholar
• 28. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S.,Lüthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., ShimamotoG., DeRose M., Elliott R., Colombero A., Tan H.L. i wsp.: Osteoprotegerin:a novel secreted protein involved in the regulation of bonedensity. Cell, 1997; 89: 309-319
  Google Scholar
• 29. Song T.J., Kim J., Yang S.H., Park J.H., Lee H.S., Nam C.M., LeeO.H., Kim Y.D., Nam H.S., Heo J.H.: Association of plasma osteoprotegerinlevels with stroke severity and functional outcome in acuteischaemic stroke patients. Biomarkers, 2012; 17: 738-744
  Google Scholar
• 30. Straface G., Biscetti F., Pitocco D., Bertoletti G., Misuraca M.,Vincenzoni C., Snider F., Arena V., Stigliano E., Angelini F., Iuliano L.,Boccia S., de Waure C., Giacchi F., Ghirlanda G., Flex A.: Assessment ofthe genetic effects of polymorphisms in the osteoprotegerin gene,TNFRSF11B, on serum osteoprotegerin levels and carotid plaquevulnerability. Stroke, 2011; 42: 3022-3028
  Google Scholar
• 31. Strand M., Soderstrom I., Wiklund P.G., Hallmans G., WeinehallL., Soderberg S., Olsson T.: Polymorphisms at the osteoprotegerinand interleukin-6 genes in relation to first-ever stroke. Cerebrovasc.Dis., 2007; 24: 418-425
  Google Scholar
• 32. Suliburska J., Bogdanski P., Gajewska E., Kalmus G., SobieskaM., Samborski W.: The association of insulin resistance with serumosteoprotegerin in obese adolescents. J. Physiol. Biochem., 2013;69: 847-853
  Google Scholar
• 33. Thrift A.G., Cadilhac D.A., Thayabaranathan T., Howard G., HowardV.J., Rothwell P.M., Donnan G.A.: Global stroke statistics. Int.J. Stroke, 2014; 9: 6-18
  Google Scholar
• 34. Ueland T., Dahl C.P., Kjekshus J., Hulthe J., Böhm M., Mach F.,Goudev A., Lindberg M., Wikstrand J., Aukrust P., Gullestad L.: Osteoprotegerinpredicts progression of chronic heart failure: resultsfrom CORONA. Circ. Heart Fail., 2011; 4: 145-152
  Google Scholar
• 35. Üstündağ M., Orak M., Güloğlu C., Tamam Y., Sayhan M.B., KaleE.: The role of serum osteoprotegerin and S-100 protein levels in patientswith acute ischaemic stroke: determination of stroke subtype,severity and mortality. J. Int. Med. Res., 2011; 39: 780-789
  Google Scholar
• 36. Wynne F., Drummond F., O’Sullivan K., Daly M., Shanahan F.,Molloy M.G., Quane K.A.: Investigation of the genetic influence ofthe OPG, VDR (Fok1), and COLIA1 Sp1 polymorphisms on BMD in theIrish population. Calcif. Tissue Int., 2002; 71: 26-35
  Google Scholar
• 37. Ziegler S., Kudlacek S., Luger A., Minar E.: Osteoprotegerin plasmaconcentration correlate with severity of peripheral artery disease.Atherosclerosis, 2005; 182: 175-180
  Google Scholar

Full text